# OnCo record paper-checkmate-057-nejm-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-057-nejm-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-057-nejm-2015" ;
  schema:name "CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer"@en ;
  schema:description "After platinum chemotherapy had failed, the PD-1 antibody nivolumab prolonged life compared with docetaxel in non-squamous lung cancer with far fewer severe side effects, and the benefit was largest in tumours expressing PD-L1."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-057-nejm-2015/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1507643>, <https://clinicaltrials.gov/study/NCT01673867> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1507643> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Borghaei H, Paz-Ares L, Horn L, et al." ;
  onco:related <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/orr/> .